Nystatin (Nystan / Nystaform / Tinaderm-M)

Nystatin (Nystan / Nystaform / Tinaderm-M) is an anti-fungal agent approved for the treatment of candidiasis. It can be also be used to prevent candidiasis in patients with HIV, particularly when they have low CD4 cell counts.1

Nystatin is available as tablets, a mouthwash and in pastilles, creams and ointments. Side-effects can include nausea, vomiting and diarrhoea at high doses.

In people with HIV, nystatin treatment is often unsuccessful, and relapses of candidiasis are common.2

Nystatin is manufactured by Bristol-Myers Squibb.


  1. MacPhail LA et al. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 12: 470-476, 1996
  2. Pons VG et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 24: 1204-1207, 1997

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.